CtrlK
MDT
NYSE
Health Care
$83.20
USD
-$0.36 (-0.43%)
At close: Jul 17, 2026, 4:00 PM EDT
Market Cap:
$107.65B
Volume:
7.7M
Previous Close
$83.56
Day Range
$82.71 - $84.69
52 Week Range
$73.31 - $106.33
Average Volume (10 Days)
8.0M
P/E Ratio (TTM)
22.42
Dividend Yield
3.38%
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
CEO
Mr. Geoffrey Martha
Headquaters
GALWAY, DUBLIN, IE
Founded
1977
Employees
95,000
Medtronic reported fiscal Q4 revenue of $9.8 billion, up nearly 10% year-over-year, marking its strongest annual growth in 10 years. The performance was driven by its cardiovascular segment, particularly cardiac ablation solutions which grew 78% globally, with pulsed field ablation expanding 145%. For fiscal 2027, the company guided to 6.75%-7.25% organic revenue growth but flagged a $250 million tariff impact, causing its earnings outlook to miss analyst expectations.
0
0
Medtronic reported fiscal 2026 revenue of $36.4 billion, up 8.4%, and Q4 revenue of $9.8 billion, up 9.9%, both beating estimates. The cardiovascular segment led growth for the third consecutive quarter, driven by 78% growth in cardiac ablation solutions. The company increased its quarterly dividend to $0.72 per share, marking 49 consecutive years of dividend increases, and guided fiscal 2027 organic revenue growth of 6.75% to 7.25%.
STE
STERIS plc
$217.84
-1.5%
0
0